Top

Published in:

24-06-2022 | Breast Cancer | Letter to the Editor

Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis”

Authors: Francesca Poggio, Marcello Ceppi, Piero Fregatti, Matteo Lambertini, Marco Tagliamento

Published in: Breast Cancer Research and Treatment | Issue 3/2022

Excerpt

We thank Bluming [1] and Nie et al. [2] for their comments to our paper “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis” [3], reflecting the interest towards this debated and important topic. This letter aims to address the raised issues. …

Bluming AZ (2022) Safety of systemic hormone replacement therapy in breast cancer survivors. Breast Cancer Res Treat 191:685–686CrossRef

Nie W, Ding H, Zou X (2022) Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.” Breast Cancer Res Treat

Poggio F, Del Mastro L, Bruzzone M et al (2022) Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat 191:269–275CrossRef

Marsden J, Whitehead M, A’Hern R et al (2000) Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 73:292–299CrossRef

Kenemans P, Bundred NJ, Foidart J-M et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10:135–146CrossRef

Borenstein M, Hedges LV, Higgins JPT et al (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1:97–111CrossRef

Franzoi MA, Agostinetto E, Perachino M, et al (2021) Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol

Title: Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis”
Authors: Francesca Poggio
Marcello Ceppi
Piero Fregatti
Matteo Lambertini
Marco Tagliamento
Publication date: 24-06-2022
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 3/2022
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-022-06590-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2022

Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer

Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer

A mixed method study of medical oncologists’ perceived barriers and motivators to addressing long-term effects in breast cancer survivors

Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence

Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer